Replies to post #53773 on Biotech Values

[DewDiligence]

> NVS – “Dynamic performance thanks mainly to the US and supported by recent launches of difficult-to-make generics…”<

Other than Omnitrope, which recent Sandoz launches can legitimately be described as difficult to make? T.i.a. Dew